The estimated Net Worth of David Goodman is at least $76.5 mil dollars as of 30 April 2024. David Goodman owns over 5,396 units of Neurometrix stock worth over $30,331 and over the last 19 years he sold NURO stock worth over $0. In addition, he makes $46,130 as Independent Director at Neurometrix.
David has made over 8 trades of the Neurometrix stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 5,396 units of NURO stock worth $23,581 on 30 April 2024.
The largest trade he's ever made was exercising 17,647 units of Neurometrix stock on 2 May 2023 worth over $24,529. On average, David trades about 1,664 units every 198 days since 2005. As of 30 April 2024 he still owns at least 7,602 units of Neurometrix stock.
You can see the complete history of David Goodman stock trades at the bottom of the page.
Dr. David E. Goodman M.D. serves as Independent Director of the Company. Dr. Goodman has been running his own independent primary care medical practice where he also manages the care of first responders (police, fire, EMS) injured in the line of duty. From 2013-2016, Dr. Goodman has served as CEO of FeetFirst, a technology-focused healthcare services company he co-founded that is committed to preventing the devastating and expensive microvascular complications of diabetes. From 2014 - 2016, Dr. Goodman served as a director of Xtant Medical (OTC QX: BONE), a comprehensive supplier of orthopedic and spine surgery products. From 2012 – 2015, Dr. Goodman served as CMO of FirstVitals, a healthcare services company focused on wellness and prevention. Since 2011, Dr. Goodman has also served as an independent consultant. During 2010, Dr. Goodman served as President and Chief Executive Officer of SEDline, Inc., a research-focused company with the mission to expand the scope and applications for neuromonitoring. From 2008 to 2009, Dr. Goodman served as Executive Vice President of Business Development for Masimo Corporation, a manufacturer of non-invasive patient monitors. From 2006 to 2008, Dr. Goodman served as an independent consultant providing product design, regulatory and analytical consulting services to medical device and biopharmaceutical companies and also served in this capacity from 2003 to 2004 and from 2001 to 2002. From 2005 to 2006, Dr. Goodman served as President and Chief Executive Officer of BaroSense, Inc., a medical device company focused on developing minimally invasive devices for the long-term treatment of obesity. From 2004 to 2005, Dr. Goodman served as President and Chief Executive Officer of Interventional Therapeutic Solutions, Inc., an implantable drug delivery systems company. From 2002 to 2003, Dr. Goodman served as Chairman, President and Chief Executive Officer of Pherin Pharmaceuticals, a pharmaceutical discovery and development company.
As the Independent Director of Neurometrix, the total compensation of David Goodman at Neurometrix is $46,130. There are 4 executives at Neurometrix getting paid more, with Shai Gozani having the highest compensation of $775,030.
David Goodman is 63, he's been the Independent Director of Neurometrix since 2004. There are 3 older and 4 younger executives at Neurometrix. The oldest executive at Neurometrix Inc. is Thomas T. Higgins, 69, who is the Sr. VP, CFO & Treasurer.
David's mailing address filed with the SEC is C/O NEUROMETRIX, INC., 4B GILL STREET, WOBURN, MA, 01801.
Over the last 20 years, insiders at Neurometrix have traded over $14,886,276 worth of Neurometrix stock and bought 3,074,896 units worth $6,396,868 . The most active insiders traders include James Edeerfield Capital Lp..., Capital Partners, Lp Topline y Capital Management, Llc Mc .... On average, Neurometrix executives and independent directors trade stock every 45 days with the average trade being worth of $133,905. The most recent stock trade was executed by Thomas T Higgins on 2 May 2024, trading 498 units of NURO stock currently worth $2,226.
neurometrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. the company maintains an active research effort and has several pipeline programs. the company is located in waltham, massachusetts and was founded as a spinoff from the harvard-mit division of health sciences and technology in 1996. for more information, please visit neurometrix.com. neurometrix markets the following products: quell® wearable pain relief technology™ quell is 100% drug free wearable technology that has changed the lives of people suffering with chronic pain. it combines clinical strength neurostimulation to treat pain with an easy-to-use app that helps people manage pain and reclaim their lives. quell is doctor recommended and designed for people with chronic back pain, arthritic pain, nerve pain, leg and foot pain, among other chronic pain conditions. quell launc
Neurometrix executives and other stock owners filed with the SEC include: